The purpose of the study is to compare the efficacy of QLS4131(SC) in combination with QL2109, with or without pomalidomide or lenalidomide, and QLS4131 (SC) in combination with QL2109, and QLS4131 (SC) in combination with Pomalidomide, and QLS4131(SC) in combination with QL2109 and Lenalidomide.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DLT
Timeframe: From time of the first dose of QLS4131 to end of DLT period (28 days)
MTD
Timeframe: Up to 2 years
ORR (Partial Response [PR] or Better)
Timeframe: Up to 2 years
Overall Minimal Residual Disease (MRD)
Timeframe: Up to 2 years